Biomarker ID | 217 |
PMID | 17713630 |
Year | 2007 |
Biomarker | Kelch repeat and BTB (POZ) domain containing 10 (krp1) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Cell Lines |
Subjects | Rat |
Regulation | Upregulated in MAT-LyLu (48 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include: Extracellular/ECM; Cell motility;Defense response; Development; MAP kinase phosphatase activity;Oxidoreductase activity; Proteolysis and peptidolysis; Regulation of cell cycle /proliferation; Regulation of transcription/ DNA-binding; Transporter activity; Ubiquitin activity; Calcium ion binding; Carboxylesterase activity; DNA repair; Enzyme inhibitor activity; Glucuronosyltransferase activity; Receptor activity; Growth factor; Induction of apoptosis; Kinesin complex; Ligase activity; Lactate dehydrogenase activity; Phosphatase activity; Transcription coactivator activity; Transferase activity; Alcohol dehydrogenase activity; Hydrolase activity; Fatty acid metabolism; |
Experiment | MAT-LyLu Vs G Cell Lines |
Type of Biomarker | Prognostic |
Cohort | Dunning rat tumor cell sublines, G (non metastatic) and MAT-LyLu (highly metastatic) were grown |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.01816 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Validated on qRT-PCR |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on human patient cohort |
Technical Name | NA |